A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer

Pfizer

Status and phase

Completed

Phase 1

Conditions

Neoplasms

Lymphoma, Non-Hodgkin

Treatments

Drug: PD-0332991

Study type

Interventional

Funder types

Industry

Identifiers

NCT00141297

A5481001

Details and patient eligibility

About

PD-0332991 may work in cancer by stopping cancer cells from multiplying. PD-0332991 is in a new class of drugs called cyclin-dependent kinase (CDK inhibitors). This research study is the first time that PD-0332991 will be given to people. PD-0332991 is taken by mouth daily.

Enrollment

74 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Advanced solid tumors (excluding SCLC and retinoblastoma) or follicular of diffuse large cell non-Hodgkin's lymphoma, histologically or cytologically proven at diagnosis which is refractory to or intolerant of established therapy know to provide clinical benefit for their condition; tumors must express Rb
Adequate blood cell counts, kidney function and liver function and and ECOG score of 0, 1, or 2.
Patients may have to have tumor biopsy before and after treatment.

Exclusion criteria

Prior stem cell or bone marrow transplant
Uncontrolled infection, unstable or sever intercurrent medical condition, or current drug or alcohol abuse
Active or unstable cardiac disease or history of heart attack within 6 months